SCHEDULE: Centessa Pharmaceuticals: Medicxi Entities Report Zero Ownership

Multiple Medicxi entities have filed a Schedule 13G amendment, reporting 0.0% beneficial ownership of Centessa Pharmaceuticals plc ordinary shares as of June 30, 2026.

Summary

• This filing is an amendment to a Schedule 13G for Centessa Pharmaceuticals plc.
• Several Medicxi entities, including Medicxi Growth I LP, Medicxi Growth Co-Invest I LP, Medicxi Ventures I LP, Medicxi Co-Invest I LP, Medicxi Secondary I LP, and Medicxi Secondary Co-Invest I LP, along with their respective general partners and manager, are listed as reporting persons.
• As of June 30, 2026, none of the reporting persons beneficially own any ordinary shares of Centessa Pharmaceuticals plc.
• The aggregate amount beneficially owned by each reporting person is 0.00 shares, representing 0.0% of the class.

Sentiment

Score: 2

Explanation: StockSavvy.ai views this filing as neutral to slightly negative due to the complete absence of beneficial ownership, indicating no significant stake or change in holdings by the reporting entities.

Negatives

• The filing indicates that none of the reporting entities hold any beneficial ownership of Centessa Pharmaceuticals plc ordinary shares.
• This suggests a complete lack of significant investment or control by these Medicxi entities in the company as of the reporting date.

Future Outlook

No forward-looking statements or guidance are provided in this filing.

Industry Context

StockSavvy.ai notes that Schedule 13G filings are typically made by institutional investors who acquire beneficial ownership of more than 5% of a class of a company's securities. The absence of any reported ownership by these Medicxi entities in this filing is unusual and suggests either a prior holding has been divested or no significant investment was made.

Stakeholder Impact

• Shareholders: The lack of reported ownership by significant investment entities like Medicxi may indicate a lack of confidence or a strategic shift away from Centessa Pharmaceuticals, which could be perceived negatively by the market.

Key Dates

Keywords

Centessa Pharmaceuticals, Medicxi, Schedule 13G, Ownership, Beneficial Ownership, Securities Exchange Act